Doxapram and neurodevelopmental outcome.
Neil N
NN
Finer
Keith J
KJ
Barrington
D002170:Canada; D002490:Central Nervous System / Q000187:drug effects* / Q000254:growth & development*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D004315:Doxapram / Q000627:therapeutic use*; D006801:Humans; D007229:Infant Welfare; D007231:Infant, Newborn; D014481:United States
D000697:Central Nervous System Stimulants; D004315:Doxapram